MedTrace Logo

Effects of Statin on Hepatocellular Carcinoma Recurrence After Liver Transplantation

NCT03490461 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 350

Last updated 2018-04-06

No results posted yet for this study

Summary

This study aims to investigate whether statin therapy can help prevent recurrence of hepatocellular carcinoma (HCC) in transplant recipients who had liver transplantation for HCC. Multiple logistic regression analysis will be performed to evaluate the association between statin therapy and the risk of HCC recurrence after LT.

Conditions

Interventions

DRUG

Statin

Patients who used statins over 1 month for the treatment of dyslipidemia after LT were enrolled as statin group.

Sponsors & Collaborators

  • Yonsei University

    lead OTHER

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-11-22
Primary Completion
2018-03-01
Completion
2018-03-01

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03490461 on ClinicalTrials.gov